Galectin Therapeutics Shares Up 11.09%; After Dropping ~80% After Failed Phase 2b Trial Dec. 5, Stock Has Made New 52-Week High Of $4.80 Today, Trading 78% Above Closing Price Day Before Drug Failure News, With No News To Justify